公开(公告)号：US20220106568A1

公开(公告)日：2022-04-07

申请号：US17427737

申请日：2020-01-21

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Changsheng LIU ,  Kai DAI ,  Jing WANG ,  Qinghao ZHANG ,  Shunshu DENG ,  Guilong LI

IPC: C12N5/0775 ,  A61P37/06 ,  A61K35/12

Abstract: Disclosed are a stem cell generator, a construction method therefor and the use thereof. The stem cell generator is formed by implanting a biomaterial loaded with active substances and/or cells, or a biomaterial with an osteogenic induction capability into animal or human bodies and producing organoids upon development.

公开(公告)号：US20150337025A1

公开(公告)日：2015-11-26

申请号：US14653276

申请日：2013-12-05

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Changsheng LIU ,  Wanli XING ,  Jing WANG ,  Jiangchao QIAN ,  Jing LIANG

IPC: C07K14/51 ,  A61K9/00 ,  A61K38/18 ,  A61K31/664

CPC classification number: C07K14/51 ,  A61K9/0019 ,  A61K31/664 ,  A61K38/1875 ,  A61K38/193 ,  C07K2319/33

Abstract: Disclosed is the use of a fusion protein in drugs for stimulating differentiation of bone marrow mesenchymal stem cells to hematopoietic stem/progenitor cells, or drugs for proliferation of granulocyte hematopoietic progenitor cells. The fusion protein has a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4. The drugs can be used for the prevention and/or treatment of (i) hematopoietic dysfunction caused by chemotherapy, (ii) hematopoietic dysfunction caused by radiotherapy, or (iii) leukopenia.

Abstract translation: 公开了在药物中使用融合蛋白来刺激骨髓间充质干细胞分化成造血干细胞/祖细胞或用于粒细胞造血祖细胞增殖的药物。 融合蛋白具有如SEQ ID NO：2或SEQ ID NO：4所示的序列。该药物可用于预防和/或治疗（i）由化疗引起的造血功能障碍，（ii）造血功能障碍引起的 放射治疗，或（iii）白细胞减少。